MetaVia Business Update
MetaVia announced that an abstract for its Phase 1 clinical trial of DA-1726, a dual GLP-1 and glucagon receptor agonist, has been accepted for an oral presentation at the Precision Liver Symposium 2026. The presentation, scheduled for November 4, 2026, will highlight data regarding weight loss and reduction in MRI-PDFF (liver fat) in patients. While the filing mentions previous trial findings, it does not disclose the specific new data points or results that will be presented at the upcoming conference.